Collegium Pharmaceutical
Yahoo Finance • 9 days ago
3 Healthcare Stocks That Concern Us
3 Healthcare Stocks That Concern Us Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising... Full story
Yahoo Finance • 10 days ago
Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks
Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks Looking back on branded pharmaceuticals stocks' Q2 earnings, we examine this quarter's best and worst performers, including Merck (NYSE:MRK) an... Full story
Yahoo Finance • 11 days ago
3 Value Stocks That Fall Short
3 Value Stocks That Fall Short Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they're out of favor. The key risk, however, is that these stocks are usuall... Full story
Yahoo Finance • 18 days ago
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to... Full story
Yahoo Finance • last month
Collegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often... Full story
Yahoo Finance • 2 months ago
Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Ian Karp President and Chief Executive Officer - Vikram Karnani Chief Financial Officer - Colleen Tupper Full Co... Full story
Yahoo Finance • 2 months ago
Collegium Pharmaceutical Q2 Earnings Call Highlights
Key Points Interested in Collegium Pharmaceutical, Inc.? Here are five stocks we like better. Second-quarter revenue rose 6% to $199.9 million, driven by strong growth in JORNAY PM and the newly acquired AZSTARYS, which helped offset decl... Full story
Yahoo Finance • 2 months ago
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
– Completed Acquisition of AZSTARYS®, Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated JORNAY PM®Quarterly Net Revenue of $46.... Full story
Yahoo Finance • 3 months ago
1 Mooning Stock to Own for Decades and 2 That Underwhelm
1 Mooning Stock to Own for Decades and 2 That Underwhelm Great things are happening to the stocks in this article. They're all outperforming the market over the last month because of positive catalysts such as a new product line, constru... Full story
Yahoo Finance • 4 months ago
As U.S. profit margins near record highs, these small-cap stocks lead on profitability
[Growth bar graph] Dougal Waters As U.S. corporate profit margins remain near historic highs, investors are increasingly looking for companies that can translate strong operating performance into sustained earnings growth. Recent data fr... Full story
Yahoo Finance • 5 months ago
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Extends Collegium’s Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 – –... Full story
Yahoo Finance • 5 months ago
Q4 Earnings Roundup: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Segment
Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking ahead, the branded pharmaceutical industry is positioned for tailwinds from adva... Full story
Yahoo Finance • 6 months ago
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly... Full story
Yahoo Finance • 6 months ago
Is Collegium Pharmaceutical (COLL) One of the Best Small-Cap Drug Manufacturers
Collegium Pharmaceutical Inc. (NASDAQ:COLL) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds. On March 24, Vikram Karnani, President and CEO at Collegium Pharmaceutical Inc. (NASDAQ:COLL), shared hi... Full story
Yahoo Finance • 7 months ago
Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million
Scott Dreyer, Executive Vice President and Chief Commercial Officer of Collegium Pharmaceutical(NASDAQ:COLL), reported the sale of 49,976 shares of common stock in open-market transactions on March 3, 2026, according to an SEC Form 4 filin... Full story
Yahoo Finance • 7 months ago
Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037
Collegium Pharmaceutical logo 5 Hot Stocks With Summer Buybacks You Can Cash In On Collegium Pharmaceutical (NASDAQ:COLL) outlined plans to acquire the ADHD drug AZSTARYS and related corporate subsidiaries from Corium Therapeutics, a tra... Full story
Yahoo Finance • 7 months ago
Collegium Strengthens ADHD Portfolio With AZSTARYS Acquisition
(RTTNews) - Collegium Pharmaceutical, Inc. (COLL) has announced a definitive agreement to acquire AZSTARYS from Corium Therapeutics for $650 million in cash, with potential milestone payments up to $135 million. The acquisition adds a dif... Full story
Yahoo Finance • 7 months ago
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – AZSTARYSExpected to Generate Over $50 Million... Full story
Yahoo Finance • 7 months ago
BrightSpring Health Services, Collegium Pharmaceutical, and Phibro Animal Health Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. The retreat in oil prices provided temporary relief to a market that was volatil... Full story
Yahoo Finance • 7 months ago
Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference
Collegium Pharmaceutical logo Key Points Collegium reported a “record-breaking” 2025 with strong net revenue and adjusted EBITDA performance, led by JORNAY PM which grew 48.9% YoY driven by ~20% volume growth, expanded salesforce (125→18... Full story